EQT

EQT is a global private equity and infrastructure firm founded in 1994, headquartered in Stockholm, Sweden. It specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies with strong growth potential. EQT invests across various sectors, including healthcare, technology, services, industrials, and real estate, with a particular emphasis on Northern and Eastern Europe, Asia, and the US. The firm seeks to unlock growth potential in its portfolio companies, positioning them as sustainable market leaders, and typically holds investments for four to eight years. EQT also prioritizes ESG and impact investments in its infrastructure portfolio.

Sofia Ahuja

Partner

Christian Shin Høegh Andersen

Managing Director, Private Equity and Investment Advisory Professional

James Arrol

Managing Director, Fund Management

Teruyuki Asaoka

Managing Director

Fouad Azzam

General Partner

Fredrik Backman

Managing Director, Client Relations

Peter Balslev

Managing Director

Johann-Christoph Balzer

Partner, EQT Value-Add Infrastructure

Eirik Benzon

Managing Director, BPEA EQT Team

William Bergström

Director

Lennart Blecher

Deputy Managing Partner

Clemens van Blitterswijk

Founder of LSP Health Economics Fund

Mark Braganza

Partner, Investment Advisory

Carolina Brochado

Partner

Marc Brown JD

Partner and Head of EQT Growth

Anna Brundtland

Managing Director

Kenneth Cheong

Partner

Wonho Choi

Vice President

Henry Connon

Associate, Private Equity and Investment Advisory Professional

Crosby Cook

Partner, Infrastructure and Investment Advisory Professional

Guy Cui

Partner

Nicholas Curwen

Managing Director

Alex Darden

Partner, President and Head of EQT Infrastructure Advisory Team Americas

Christina Drews

COO and Executive Committee

Asis Echaniz

Partner and Head of Spain

Andreas Eichelberger

Director

Frederik Elwing

Managing Director

Victor Englesson

Partner

Ali Farahani

Partner

Frank Feng

Managing Director

Andreas Fischer

Partner

Mark Fogle

Partner and Head of EQT Exeter APAC

David Forde

Partner

Juho Frilander

Managing Director

Florian Funk

Partner, Private Equity

Guillermo Garcia-Barrero

Managing Director

Henrik Giver

Managing Director

Simon Gold

Managing Director, Client Relations and Capital Raising

Wolfgang Gorny

Partner, Private Equity

Alexander Greenbaum

Partner, Active Core Infrastructure Advisory Team and Investment Advisory Professional

Fabian Grone

Partner, Head of Asia

Floris van Halder

Managing Director

Sean Ham

Partner and Head of Asia Pacific

Jerry He

Partner and Head of China, Mid Market Asia Advisory Team

Frank Heckes

Partner, Private Equity

Erika Henriksson

Partner, Private Equity

Jak Hestnes

Managing Director and Board Member

Gerran Ho

Managing Director, Mid Market Asia

Christian Horn

Managing Director

Sara Huda

Managing Director and Head of Investment Services

Johan Hylander

Managing Director

Bert Janssens

Head of Private Equity Europe and Global Co-Head of Services, Private Capital

Patrick Jaslowitzer

Managing Director

Neha Jatar

Managing Director

Yan Jiao

Partner

Herman Johre

Associate

Maarten de Jong

Partner, EQT Private Equity

Lars Jörnow

Partner

Kosmo Kalliarekos

Partner

Viviana Kane

Managing Director

Masahiko Kato

Managing Director and Head of Infrastructure Japan

Matthew Kestenbaum

Managing Director

Nils Ketter

Partner

Paul Kim

Managing Director

Gleb Kozyritskiy

Managing Director

Arvindh Kumar

Partner and Co-Head of Technology Sector Team

Elias Källström

Managing Director

Ulrich Kollensperger

Partner

Tobias Kung

Managing Director, Infrastructure

Priscilla Lam

Managing Director, Portfolio Monitoring

Lance Lan

Managing Director, Exit Management

Adam Larsson

Managing Director

Kenneth Lau

Associate

Edward Lavish

Managing Director, Portfolio Risk and Transactions

Eu Han Lee

Partner, Debt Capital Markets

Alex Lee

Partner

Hong Yong Leong

Partner

Janice Leow

Partner

William Liang

Director of European Firm

Benjamin Lim

Director

William Lindström

Managing Director

Gebhard Littich

Managing Director

Nicholas Macksey

Partner

Madeleine Magnerius

Director

Paola Maleh

Partner and Head of EMEA

Francesco Malvezzi

Managing Director, Infrastructure

Tadashi Maruoka

Partner

Axel Masucci

Managing Director

Arnav Mitra

Director

Mikael Moll

Managing Director, Public Value

Pascal Noel

Managing Director

Tetsuro Onitsuka

Partner and Head of Private Equity Japan

Alex Paganini

Associate, Infrastructure

Isabel De Paoli

Partner, Healthcare

Sydney Pardey

Managing Director

Tyler Parker

Managing Director

Daniel Perez

Partner

Christopher Popp

Managing Director

Shane Predeek

Partner

Vai Rajan

Head of EMEA Private Wealth Capital Raising and Director - Client Relations and Capital Raising

Thomas Rajzbaum

Managing Director and Partner, EQT Infrastructure

Hermann Rauch

Managing Director

Vera Rebanova

Partner, Client Relations and Capital Raising

Matthias Riefer

Managing Director, Private Equity

Niklas Ringby

Partner

Patrick Rodden

Managing Director and Head of Infrastructure for Australia and New Zealand

Maxwell Roitstein

Associate

Joakim Rubin

Partner

Isidoor Rutten

Partner and Head of Private Equity Benelux

Rob Ryan

Managing Director, Market Risk

Darlene Sammon

Partner

Carlos Santana

Partner, Private Equity

Anthony Santospirito

Partner

Mika Saukkonen

Managing Director, Infrastructure

Matthew Scattarella

Partner

Brendan Scollans

Partner

Nirav Shah

Partner, EQT Value-Add Infrastructure

Hemant Sharma

Managing Director

Piyush Singhvi

Managing Director, Infrastructure

Carl Sjölund

Partner, Infrastructure

Jared Small

Managing Director

Georg Stadler

Partner, Infrastructure

Dominik Stein

Partner and Head of EQT Growth Advisory Team

Joshua Stone

Managing Director, FO Head of Strategic Initiatives

Alexander Strassburger

Managing Director

Marc-Alexander Straubinger

Managing Director

Sang Jun Suh

Partner

Anna Sundell

Partner, Infrastructure

Carl Svantesson

Partner

Miriam Tawil

Partner and Investment Advisory Professional

Michiel Thiessen

Managing Director

Elly Thio

Managing Director

Erwin Thompson

Partner, Infrastructure

Matteo Thun

Partner

Andrew Tirbeni

Managing Director, EQT Client Relations and Capital Raising

Wei Tor

Managing Director

Juan Vargas

Partner

Jan Vesely

Partner, Infrastructure

Marcus Wallinder

Partner and Deputy Head of Client Relations and Capital Raising

Forrest Wang

Managing Director, Private Equity

Ethan Waxman

Partner

Rickard Wilson

Managing Director

Matthias Wittkowski

Partner

Ken Wong

Partner and Head of Asia Pacific, Infrastructure

Philipp Worner

Director, Private Equity

Dayea Yeon

Managing Director and Head of Private Capital Korea

Shuting You

Managing Director

James Yu

Partner and Senior Bank Relationship Manager

Julia Zhu

Managing Director

John Österlund

Managing Director

Zoe Zhu

Director

Past deals in Medical Devices

Perfuze

Venture Round in 2025
Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

Cornerstone Robotics

Series C in 2025
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.

NUA Surgical

Series A in 2024
NUA Surgical is an innovative start-up located at the Innovation Hub in Galway, Ireland, focused on enhancing women's health through advanced medical devices. The company has developed a patented surgical retractor specifically designed to improve the safety and efficiency of cesarean deliveries. By concentrating on research and development, NUA Surgical aims to provide obstetricians with tools that facilitate superior surgical outcomes, ultimately making C-sections safer for patients.

Sequana Medical

Post in 2024
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Asceneuron

Series C in 2024
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Binx

Series F in 2024
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Onward

Post in 2024
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Onera Health

Series C in 2024
Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.

AgomAb Therapeutics

Series C in 2023
AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Xeltis

Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Xeltis

Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Cardiac Dimensions

Series D in 2023
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

SHL Medical

Secondary Market in 2022
SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

Vara

Series A in 2022
Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

SPT Labtech

Acquisition in 2022
SPT Labtech is a manufacturer and designer of automated instrumentation and consumables for life science research. The company specializes in enhancing agility, efficiency, and productivity across various applications, including drug discovery, structural biology, molecular biology, and genomics. Its product portfolio focuses on minimizing assay volumes, streamlining workflows, and reducing material handling costs, thereby empowering life scientists to accelerate their research. SPT Labtech emphasizes collaboration and deep application knowledge, which informs its research and development efforts. The company is committed to addressing existing customer challenges through innovative solutions, driven by a strong ethos of customer-centricity. Additionally, its extensive expertise allows SPT Labtech to manage the entire life cycle of its products, from initial design and engineering to final manufacture and support, ensuring high-quality technical assistance and fostering strong client relationships.

Perfuze

Series A in 2022
Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

ViCentra

Series C in 2021
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Meine Radiologie Holding

Acquisition in 2021
Meine Radiologie Holding GmbH specializes in providing radiological and nuclear medicine services, focusing on imaging diagnostics and radiation therapy for both malignant and benign diseases. The company supports radiology practices by acting as a financial investor and professional management partner, particularly in succession planning. Through its efforts, Meine Radiologie Holding aims to create added value for doctors, employees, referrers, and patients by optimizing central and local processes.

Binx

Series E in 2021
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Onward

Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Neurent Medical

Series B in 2021
Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015. The company focuses on developing innovative solutions for treating rhinitis, including both allergic and non-allergic forms. It offers a single-use, minimally invasive device designed for ENT surgeons that utilizes radio-frequency technology to provide non-surgical interventions for chronic rhinitis. The device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it employs a microelectrode array to deliver targeted energy. This approach interrupts the autonomic function within the mucosal structures of the nasal cavities, effectively reversing the inflammatory process. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs associated with traditional surgical procedures.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

ViCentra

Venture Round in 2020
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Health Management International

Private Equity Round in 2020
Health Management International Ltd is a regional private healthcare provider operating in Singapore, Malaysia, and Indonesia. The company owns two tertiary hospitals in Malaysia and a healthcare training center in Singapore, along with a network of representative offices across the three countries. It specializes in delivering a range of medical services, including cardio-vascular care, digestive health, minimally invasive surgeries, and diagnostic services. By focusing on both local and international patients, Health Management International aims to enhance the accessibility and quality of healthcare in the region.

SHL Medical

Private Equity Round in 2020
SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

Aldevron

Acquisition in 2019
Aldevron, LLC is a contract science organization based in Fargo, North Dakota, that specializes in the production of biological products, including plasmid DNA, proteins, antibodies, and nucleic acids. Founded in 1998, the company serves academic, research institutions, and the pharmaceutical and biotechnology sectors, focusing on applications in gene therapy and gene editing. Aldevron offers a range of services such as plasmid DNA production, protein production, antibody discovery, and mRNA production, as well as custom manufacturing solutions. Its products support various research and clinical applications, including DNA vaccines and therapeutic gene transfer studies. The company also provides additional services like gene synthesis, antibody processing, and stability services for distribution. Aldevron operates both in the United States and Europe, contributing to the development of innovative treatments for diseases, including cancer and rare disorders.

WS Audiology

Acquisition in 2019
WS Audiology A/S is a manufacturer and distributor of hearing instruments and audiological solutions, headquartered in Lynge, Denmark. Established in 2019 through a partnership between Sivantos and Widex, the company aims to enhance hearing care for individuals with hearing needs. Its product offerings include a comprehensive range of hearing aids, such as receiver-in-the-ear devices, assistive listening devices, and solutions for single-sided deafness. Additionally, WS Audiology provides accessories like hearing aid batteries, remote controls, and electronic drying stations. The company's diverse product spectrum caters to various price categories, ensuring that those with hearing loss have access to effective solutions for improved hearing and understanding.

Atlantic Therapeutics Limited

Series B in 2019
Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Karo Healthcare

Acquisition in 2019
Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

Endotronix

Series D in 2018
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

Zemax

Acquisition in 2018
Zemax, LLC specializes in developing software for optical and illumination design, catering to various industries including aerospace, defense, medical, and life sciences. Founded in 2014 and based in Kirkland, Washington, the company provides tools for designing projection lenses, binoculars, collimating lenses, laser lenses, and biomedical imaging systems. Zemax's software is recognized for its technical power, user-friendliness, and accuracy, enabling optical engineers to address a wide range of design challenges. In addition to its software offerings, Zemax also provides training and support services, enhancing the workflow and communication between optical and mechanical engineers to facilitate efficient and precise optical component design through physics-based optimization.

Simplify Medical

Series B in 2018
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

Xeltis

Series C in 2017
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Clinical Innovations

Acquisition in 2017
Clinical Innovations is the largest healthcare manufacturer exclusively focused on labor and delivery. Already a market leader in several categories with products such as the Koala® Intrauterine Pressure Catheter and Kiwi® Vacuum-Assisted Delivery System, Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Since its inception in 1993, Clinical Innovations has consistently expanded its worldwide presence, becoming the market leader in several product categories. This growth has fueled the ability to invest in new product ideas where innovation makes the difference. And with a management team with extensive experience in the medical device industry, Clinical Innovations possesses the working knowledge to develop those new product ideas into industry-changing specialty devices. Clinical Innovations is dedicated to quality and customer service. With ISO13485 certification and strong relationships with top worldwide medical distributors, Clinical Innovations has the systems and infrastructure in place to promptly respond to market trends and customer suggestions. Clinical Innovations is a Prizker Group Company.

Simplify Medical

Series B in 2017
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

Ottobock

Private Equity Round in 2017
Ottobock is a designer and manufacturer of prosthetic limbs dedicated to enhancing the mobility and quality of life for individuals with disabilities. The company focuses on innovative solutions, offering products such as a computerized knee that adapts its resistance to accommodate various walking gaits, and a fully articulated robotic hand prosthesis. These advancements enable users to overcome challenges associated with their disabilities, promoting independence and active lifestyles. Driven by a commitment to innovation and the desire to provide optimal support for those in need, Ottobock strives to improve the overall well-being of its customers.

Binx

Series D in 2017
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Vivasure Medical

Series C in 2016
Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Mint Solutions

Series B in 2016
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Rotation Medical

Series B in 2016
Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.

Onward

Series A in 2016
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

ViCentra

Series B in 2016
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Xeltis

Series B in 2015
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Sequana Medical

Series C in 2015
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Kuros Biosciences

Post in 2015
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Neuravi

Series B in 2015
Neuravi, established in 2009 and based in Galway, Ireland, specializes in the design and development of clot retrieval devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries, collaborating with international researchers and clinicians to advance understanding and treatment of ischemic stroke. As of 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Xeltis

Series B in 2014
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

Curetis

Series B in 2014
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Sivantos

Acquisition in 2014
Sivantos is a leading global manufacturer of hearing aids, with a strong presence in many countries. With a history of over 100 years, they have developed and manufactured one out of every four hearing aids used worldwide. Their portfolio includes well-known brands such as Siemens, Signia, Audio Service, Rexton, and A&M, along with accessories, fitting software, smartphone apps, and diagnostics workflow solutions. Employing about 5,000 people across more than 25 countries, Sivantos is dedicated to helping hearing-impaired individuals enjoy the sound of life.

Mint Solutions

Series A in 2014
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Rotation Medical

Series B in 2014
Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.

Binx

Series B in 2014
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

IlluminOss

Series C in 2012
IlluminOss Medical, Inc., established in 2007 and headquartered in East Providence, Rhode Island, is a medical device company specializing in orthopedic fracture repair. It designs, develops, and markets products based on its proprietary IlluminOss System, which employs a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants for bone stabilization. This minimally invasive technology is particularly suited for treating osteoporotic and compromised bone. The company's products are CE-marked and FDA-cleared for various anatomical sites and are distributed in several European countries.

BSN medical

Acquisition in 2012
BSN medical is a global leader in the healthcare market, specializing in compression therapy, wound care, and orthopedics. Based in Luxembourg, the company manufactures a range of medical products designed to provide effective solutions for caregivers and patients. Its offerings focus on the treatment of acute, chronic, and hard-to-heal wounds, ensuring a seamless progression of therapy. BSN medical integrates strong technological competencies with a broad portfolio in wound care, vascular diseases, and non-invasive orthopedics, addressing the need for simplified and efficient treatment options. The company is committed to developing high-quality branded products that support a comprehensive continuum of care.

ATOS MEDICAL

Acquisition in 2011
Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.

Binx

Series B in 2011
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Mendor

Series B in 2011
Mendor is a Finnish company focused on designing, developing, and marketing innovative diabetes management products. It has introduced a portable, all-in-one blood glucose meter alongside a web-based software application aimed at facilitating daily diabetes management. Mendor's products are developed in collaboration with users and diabetes experts to meet the specific needs of individuals who require regular blood glucose monitoring. Additionally, the company offers patented software systems that provide real-time data on diabetic care, which enhances the efficacy and efficiency of diabetes treatment for both patients and caregivers.

Sapiens Steering Brain Stimulation

Series A in 2011
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Nexstim

Venture Round in 2011
Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Curetis

Series A in 2009
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

HTL-STREFA

Acquisition in 2009
HTL-Strefa is the globally unrivalled, leading developer and provider of blood micro-sampling medical devices with a 44% global market share by volume in safety lancets, with a strong and growing global position in personal lancets and pen needles.

BMEYE

Series A in 2009
BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Nexstim

Venture Round in 2007
Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

FlowCardia

Series C in 2007
FlowCardia, Inc. is a medical device company established in 2002, specializing in the design and development of catheter-based technologies aimed at overcoming chronic total occlusions (CTOs) in coronary and peripheral arteries. CTOs present significant challenges in interventional therapy, often resulting in patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia's innovative solutions seek to address this critical gap in treatment options, enhancing the safety and efficacy of procedures for patients with these difficult-to-treat conditions.

Isto Technologies

Series E in 2007
ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.

BMEYE

Series A in 2006
BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Gambro Group

Acquisition in 2006
Gambro is a global medical technology company specializing in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, as well as other extracorporeal treatments for chronic and acute patients. Founded in 1964, Gambro has been a pioneer in dialysis technology, which is critical for patients suffering from organ failure, particularly since kidney transplantation is often not a viable option due to donor shortages. The company innovates in various areas, including hemodialysis, peritoneal dialysis, renal intensive care, and hepatic care, providing solutions that enhance treatment quality and efficiency in clinics and intensive care units. With around 8,000 employees, Gambro operates 13 production facilities across multiple countries and has a presence in more than 90 countries worldwide, demonstrating its commitment to improving patient care through advanced medical technologies.

KaVo Kerr Group

Debt Financing in 2005
KaVo Kerr is a prominent organization in the dental industry, formed by the merger of two global leaders dedicated to providing high-quality dental products and services. With over a century of experience, KaVo has built a strong reputation among dental professionals, including dentists, dental technicians, and hygienists. The company offers a wide range of products, including imaging systems, treatment units, instrumentation, laboratory equipment, and educational resources. Its imaging solutions encompass both analog and digital technologies for extra-oral and intra-oral applications, serving clients worldwide through established brands like Soredex and Instrumentarium Dental. KaVo Kerr's commitment to innovation and quality is evident in its continuous efforts to support the dental community and enhance patient care.

Palodex

Private Equity Round in 2005
Palodex is a manufacturer of dental imaging products.

Metall Technologie Holding

Debt Financing in 2005
Metall Technologie Holding is a German manufacturer specializing in heat treatment industrial furnaces. The company produces a range of furnaces including vacuum, continuous, atmospheric, and protective gas furnaces, catering to diverse sectors such as aeronautics, automotive, medical, and steel manufacturing. Their furnaces are utilized for various heat treatment processes, including gas and oil quenching, brazing of metals, sintering, tempering, annealing, and other specialized treatments like low-pressure carburizing, nitriding, and cryogenic treatment. Metall Technologie Holding serves a global clientele that includes heat treatment contractors and equipment manufacturers, providing advanced solutions for industrial heating applications.

HemoCue

Acquisition in 1999
HemoCue AB specializes in the development and production of medical diagnostic products aimed at point-of-care testing. The company offers innovative microcuvette diagnostic systems that provide lab-quality results for essential blood and urine tests, including measurements of hemoglobin, glucose, white blood cell count, and urine albumin. These tests are crucial for managing conditions such as anemia, malnutrition, diabetes, and infections. By enabling healthcare institutions to perform accurate and timely diagnostics at the point of care, HemoCue enhances the ability to monitor, detect, and evaluate various health conditions effectively. The company's focus on efficiency ensures that these vital tests can be conducted easily and quickly, making them accessible to a broader range of healthcare providers.

Pulnovo Medical

Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.